Nordic Bioscience

Nordic Bioscience’s biomarker technology helps analyze tissue health, addressing diseases like fibrosis or tissue loss.

Nordic Bioscience offers CAP/CLIA-accredited lab services, including regulatory expertise and biomarker measurements.

A liquid biopsy enabling the identification of cancer patients for clinical trial enrichment and patient stratification.

Precision medicine starts with patient identification: NordicPRO-C6 (Endotrophin) as the next-generation biomarker assay for trial enrichment in HFpEF

Detailed profiling of C4G, C4M, and PRO-C4 across untreated (n=43-48) and treated MS patient groups. C4G (T-cell activity) decreases significantly during treatment (p<0.001). C4M (BM degradation) and PRO-C4 (BM formation) are pharmacodynamically modulated.

After dosing, C4G, C4M, and PRO-C4 decrease. When patients are taken off treatment, all three biomarkers rise over weeks 21 to 61, indicating returning disease activity. This supports biomarker-guided re-dosing rather than fixed-interval protocols.

Nordic Bioscience provides scientific resources on biomarker research and drug development, including publications, webinars, and videos about extracellular matrix pharmacology and precision medicine.

Nordic Bioscience will present biomarker applications in gastrointestinal diseases at UEG Week 2026 in Barcelona, Spain.

Nordic Bioscience secured KKR investment to expand its R&D services, diagnostics platform, patent portfolio, and drug development.

A study by Signe Holm Nielsen, Morten Karsdal, and Anne-Christine Bay-Jensen identified CPa9-HNE as a blood-based biomarker for multiple sclerosis.

Open positions

Nordic Bioscience provides manual ELISA ‘Kit in a Box’ products for ECM research in preclinical and translational studies.

Prof. Dr. Morten Karsdal joined Nordic Bioscience in 2001, became CEO in 2010, and led the development of FDA-approved diagnostics and over 100 biomarker assays.

Nordic Bioscience specializes in extracellular matrix research, with over 30 years of experience in biomarker development and more than 750 peer-reviewed publications.

Nordic Bioscience offers biomarker and lab services for research inquiries.

The page explains how the Nordic ProteinFingerPrint Technology quantifies extracellular matrix protein fragments in blood to create biomarkers for precision drug development.

Nordic Bioscience’s Code of Conduct outlines ethical and legal standards for its directors, officers, employees, and representatives.

Nordic Bioscience A/S owns this website, based in Herlev, Denmark, with legal protections for its content.